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Objective: Extra-corporeal membrane oxygenation (ECMO) is a treatment for Persistent 
Pulmonary Hypertension of the Newborn (PPHN) with high mortality. Hypothesis: the ECMO 
circuit results in inflammatory responses that mitigate against successful weaning. 
Design: Single centre prospective observational feasibility study. 
Setting: Paediatric Intensive Care Unit 
Patients: Twenty-four neonates requiring ECMO support for PPHN. 
Interventions: None 
Measurements and Main Results: The reference outcome was death or more than 7 days 
of ECMO support. Other outcomes inceluded serial measures of plasma-free haemoglobin 
and markers of its metabolism, leucocyte, platelet and endothelial activation, and biomarkers 
of inflammation. Of 24 participants recruited between February 2016 and June 2017, 10 died 
or required prolonged ECMO support. These patients were sicker at baseline with higher 
levels of plasma-free haemoglobin within 12 hours of cannulation (geometric mean ratio 
1.92, 95% confidence intervals 1.00-3.67, p=0.050) but not thereafter, versus those requiring 
<7 days ECMO. Serum haptoglobin concentrations were significantly elevated in both 
groups. Patients who died or required prolonged ECMO support demonstrated elevated 
levels of platelet-leucocyte aggregation, but decreased concentrations of mediators of the 
inflammatory response: interleukin-8, C-reactive protein and Tumour Necrosis Factor α. 
Conclusion: Clinical status at baseline and not levels of plasma-free haemoglobin or the 
systemic inflammatory response may determine the requirement for prolonged ECMO 












































































Persistent Pulmonary Hypertension of the Newborn (PPHN) complicates 1–2 per 1000 live 
births, primarily affecting full term and late preterm babies.1 Some neonates with PPHN and 
severe respiratory failure require Extracorporeal Membrane Oxygenation (ECMO) support. 
This reduces mortality rates from >80% to 10-20%.2 However, ECMO remains an invasive 
form of life support. Some 74% of neonates with PPHN develop complications while on 
ECMO with cardiovascular and renal complications amongst the most common.3 The ECMO 
circuit causes haemolysis and systemic inflammation along with leukocyte and platelet 
activation that can lead to organ injury and prolonged cannulation times.4-7 Severe 
haemolysis and rise in plasma-free haemoglobin (PFH) have been reported in over 10% of 
neonatal ECMO cases.8-11 PFH is highly reactive and can oxidize multiple species including 
proteins and membrane lipids causing inflammation, endothelial injury and organ 
dysfunction.12-17 Elevated PFH may also contribute to persistent pulmonary hypertension.18-21 
These observations led us to hypothesise that damage to red blood cells by the exposure to 
the ECMO circuit results in inflammatory responses that mitigate against successful weaning 
from ECMO. As a first step to testing this hypothesis, we evaluated the feasibility of 
measuring PFH and its metabolism, cellular activation processes, and inflammation, in 











































































Materials and Methods  
Study Population 
The Markers of Inflammation and Lung recovery in ECMO patients for Persistent Pulmonary 
Hypertension of the Newborn (PPHN): MI-ECMO study, was a prospective, single-centre 
observational feasibility study. The study was reviewed by the ‘North East – York’ Research 
Ethics Committee on 11th December 2015, and granted a favourable ethical opinion on 23rd 
December 2015. Neonates (<30 days of age) having a diagnosis of PPHN and requiring 
ECMO support were eligible for inclusion. We excluded neonates with PPHN caused by a 
congenital heart pathology or those requiring ECMO for a congenital heart disease. We 
recruited consecutive patients referred to the Glenfield Hospital (a regional ECMO centre in 
the UK) according to the prevalent ECMO referral system who met the inclusion/exclusion 
criteria. Emergency assents were obtained from patients’ parents/legal guardians within 12 
hours of cannulation and full consents were obtained within 24 hours. Study withdrawal 
occurred at the parent/guardian’s request or if the patient was found not to meet all the 
inclusion criteria. In the event of withdrawal, we requested that all patient’s data and tissues 
collected until that time were retained for analysis. The study had ethical approval (REC 
reference 15/NE/0398). The trial protocol was registered (NCT02940327) and is attached as 
a digital supplement. The corresponding author (MJW) attests to the validity of the data, its 
analysis, and interpretations, on behalf of all the co-authors. 
Outcome measures 
Outcomes of interest included markers of haemoglobin and iron metabolism (plasma free 
haemoglobin, bilirubin, haptoglobin, ferritin, transferrin, total and catalytic iron), markers of 
platelet, leukocyte and endothelial cell activation (please see Research procedures below) 
and markers of the systemic inflammatory and acute phase response (interleukin (IL-) 1, IL-
6, IL-8, IL-18, Tumour Necrosis Factor α (TNFα), Monocyte chemoattractant protein 1 
(MCP1), C-reactive protein (CRP), fibrinogen) were measured in arterial blood at four time 








































































decannulation or immediately prior to termination of ECMO support in case of death or 
treatment withdrawal. 
Research Procedures 
PFH levels were estimated by measuring absorbance at 415, 450 and 700 nm of citrated 
plasma samples using EnSpire spectrophotometer (PerkinElmer, Waltham, USA) and 
calculated as described in Fairbanks et al.22 Total iron was measured in citrated plasma 
samples using Iron Assay Kit (Abcam, Cambrige, UK). Catalytic iron was estimated using 
bleomycin method, as described in Burkit et al.23 Platelet and leukocyte activation, and 
leukocyte-platelet interactions were measured using flow cytometry (CyAn ADP, Beckman 
Coulter, Pasadena, USA) in citrated blood with specific fluorescently-labelled antibodies: 
PAC-1 (against activated GPIIb/IIIa, BD Biosciences, Abingdon, Oxford, UK), CD41 
(Affymetrix, Santa Clara, USA) and CD62P (Abcam, Cambridge, UK) for platelets; CD64, 
CD163, CD11b (Affymetrix) for leukocytes; and CD14, CD16, CD41 (Affymetrix) for 
leukocyte-platelet interactions. Cytokines (IL-1, 6, 8, 18, TNFa) and soluble ICAM1, as a 
marker of endothelial activation, were measured in citrated plasma using MAGPIX platform 
(Luminex Corporation, Austin, USA) and magnetic Luminex assays (BioTechne, Abingdon, 
UK). Troponin (Enzo Biochem, Farmingdale, USA), Haptoglobin (Abcam), ferritin and 
transferrin (ThermoFisher Scientific, Waltham, USA), were measured in plasma using ELISA 
DS2 Dynex platform (Worthing, UK). Levels of bilirubin, alkaline phosphatase, pH, pO2, 
pCO2, SaO2 and lactate were collected from routine hospital diagnostic procedures. 
Clinical procedures 
Pre-ECMO care and ECMO indication: Eligible patients received standard care during the 
pre-ECMO period, according to the different respiratory failure aetiology and protocols from 









































































The ECMO circuit and cannulation: The ECMO circuit consisted of vascular access 
cannulas (Biomedicus, Medtronic, Dublin, Ireland), polyvinyl chloride tubing for blood 
extracorporeal circulation (Leicester Neonatal circuit, Chalice Medical, Worksop, UK), a 
pump console (2nd generation Centrimag, Thoratec Corporation, Pleassanton, USA), a 
centrifugal pump (Centrimag, Thoratec Corporation) and head (PediVAS Blood pump., 
Thoratec Corporation) and an oxygenator (Paragon infant PMP oxygenator, Chalice 
Medical). Cannulation was always performed using an open surgical approach. VA (veno-
arterial) or VV (veno-venous) cannulation was chosen based on the clinical status of the 
patient and the availability of the correct material by the attending clinician. VA ECMO 
involved surgical cannulation of the right common carotid artery and internal jugular vein, 
with the tip of the venous cannula 10fg Biomedicus (Medtronic, Minneapolis, USA) advanced 
into the right atrium and the arterial catheter positioned at the junction of the right common 
carotid artery and aortic arch. VV ECMO involved insertion of a 13F (OriGen Biomedical, 
Austin, USA) arterial / venous cannula advanced to the right atrium via the right internal 
jugular vein.  
ECMO management: Established Glenfield ECMO centre protocols were used. In VA-
ECMO flows were typically maintained at about 100-120 mL kg-1 min-1 to achieve normal 
saturation (SvO2 > 65%), with a controlled pCO2 to achieve a normal pH. The target of 
arterial blood oxygen saturation during VV ECMO was >85% with a venous oxygen 
saturation > 60% and low lactates with targeted flow rates of 80 mL kg-1 min-1. Sweep gas 
was usually maintained at a FiO2 100% and regulated on the pCO2 basis; the usual starting 
ECMO flow:sweep gas ratio was 1:1.  
Ventilator Management: During ECMO, patients were commonly ventilated in a “lung rest” 
setting defined as a respiratory rate of 10 breaths minute-1, PEEP (positive end expiratory 
pressure) of 10 cmH20 and pressure over PEEP 10 cmH20 with FiO2 40% for VA ECMO and 








































































Haemodynamic support: During VA-ECMO patients received haemodynamic support in 
addition to the respiratory support, and the usual inotropes requirement was reduced or null. 
During VV-ECMO inotropic or vasoactive support was used to maintain an adequate 
perfusion and cardiac output defined by general practice targets: Mean Arterial Blood 
Pressure (MABP) > 40 mmHg, lactate < 2 mmol L-1, central venous saturation > 60% with 
evidence of end organ perfusion e.g. urine output. 
Anaesthesia induction: The anaesthetic technique used a standard unit protocol that while 
titrated to effect, is typically Ketamine 2 mg kg-1 for sedation and Atracurium 1 mg kg-1 as a 
neuromuscular blocking agent. Underlying sedation was modified according to the 
requirements of the patient and deviations from the protocol were recorded. Details of 
concomitant medications and therapy including generic drug name, dose, route, frequency, 
duration and indication were recorded. 
Fluid Management: Target urine output was > 0.5 mL kg-1 h-1. This was maintained using 
fluid boluses or diuretics at the discretion of the attending clinician. In some circumstances 
the clinician can choose CRRT (continuous renal replacement therapy) according the local 
protocols and fluid balance. 
Transfusion: The standard unit protocol is transfusion with 10 mL kg-1 of allogenic red cells 
if the heamoglobin< 13g dL-1 and SvO2 < 65% or in the presence of bleeding. Non red cell 
components were administered according to standard unit protocols, with the indication, 
volume and timing of their administration recorded. 
Weaning: Clinician and patient clinical status guided ECMO weaning. VA ECMO was 
typically with “retrograde flow”, in this case the flow in the cannula is reversed inside the 
system using the ECMO as a brake and not as an engine. With this kind of procedure, the 
observational weaning time is prolonged with less clotting risk for the circuit. In VV ECMO, 
the support blood flow is maintained but the sweep gas is unplugged, the patient is fully 
ventilated to assess the lung function. Failure to wean the patient results in restarting ECMO 









































































Continuous data are presented as the mean (standard deviation, SD) or median 
(interquartile range, IQR) as appropriate. Categorical data are presented with frequency and 
percentage. Duration on ECMO was recorded in terms of hours and converted to days by 
dividing by 24. Patients were classified as prolonged stay if they stayed on ECMO for at 
least 7 days or if they did not survive to discharge (patients who died cannulated or after 
weaning). Patients not experiencing a prolonged stay were surviving patients who stayed on 
ECMO for less than 7 days. Using the linear mixed effects model with patients as random 
effect, we compared the trajectory of outcome measures between those experiencing a 
prolonged stay on ECMO and those not. Separate models were built for each of the outcome 
measures. All models included the main effects of group (prolonged stay or not) and time (5 
time points) together with the group—time interaction term. A significant interaction term 
indicates that the two groups exhibit different trajectories of the outcome or the effect of 
groups depends on the time points. Models with a significant group effect but insignificant 
interaction indicates the effect of groups are similar over the time points. Interaction or group 
effects were considered significant if p-value < 0.05. For laboratory measurements and 
ECMO and blood gas parameters where data prior to ECMO or at start of ECMO were 
measured, the models would be adjusted for these baseline values.  Outcome data analysed 
on a logarithmic scale would be transformed back to the original scale after the analysis and 
results reported as geometric mean. A p-value of <0.05 was considered statistical 
significance. No adjustment for p-values has been made for multiple comparisons as this 
was a feasibility study. All analyses were performed with SAS version 9.4 (SAS Institute Inc., 











































































Between February 2016 and June 2017, we screened 52 neonates referred to the Glenfield 
Hospital for ECMO support, of which 24 with PPHN were eligible. Informed full consent was 
obtained from parents in every case. Figure 1 and Supplemental Table 1 show participant 
flow and completeness of data for individual endpoints. The reference outcome (7+ days on 
ECMO) occurred in 10 (41.7%) participants, two of which died while cannulated and 1 who 
died 6.3 days after weaning. A further 14 neonates with PPHN (58.3%) stayed on ECMO for 
<7 days and survived to discharge (<7 days). There was no difference between the two 
groups with respect to age (median 2 days), gestational age (median 40 weeks), male: 
female ratio, or birth weight (median 3.2kg) (Table 1). The aetiology of PPHN differed 
significantly between the two groups; congenital diaphragmatic hernia accounted for 8/10 
(80%) in the 7+ days group and meconium aspiration syndrome (MAS) accounted for 12/14 
(85%) of the <7 days group (Table 1). This was reflected by differences in ventilation 
strategies at baseline; 10/10 (100%) in the 7+ days group underwent HFOV whereas 7/14 
(50%) of the <7 days group underwent SIMV (Table 1).  
Baseline Clinical Status 
 A greater proportion of participants in the 7+ days group were haemodynamically unstable 
prior to cannulation; n=7/10 (70%) versus n=5/14 (36%, Table 2). Arterial pCO2 and serum 
lactate concentrations were higher in the 7+ days group, and arterial SaO2 was lower. None 
of these changes reached conventional statistical significance (P<0.05). Baseline values for 
PIM2 (mortality risk) or PMODS (organ dysfunction) scores at ICU admission were not 
significantly different between the two groups. At baseline participants in the <7 days group 
were less acidotic; mean PH 7.3, SD 0.08 versus 7.3, SD 0.12, pBaseline=0.018, but had 
significantly higher levels of  CRP(median 39 mg L-1, IQR 11-18 versus 6 mg L-1, IQR 5-15, 
pBaseline=0.019) and alkaline phosphatase (median 198 iu L-1, IQR 113 – 613, pBaseline=0.03 vs 









































































There was no difference between the groups with respect to use of VA (n=21) versus VV 
ECMO (n=3), choice of prime (blood/crystalloid), pump flows, or sweep (Tables 1 & 2). 
Participants in the <7 days group spent a median of 80 hours (IQR 59-91), and patients in 
the 7+ days group spent a median of 292 (186-360) hours on ECMO. Mean arterial blood 
pressure was similar between the groups for the duration of ECMO support (Supplemental 
Table). SaO2 and PaO2 were higher (all participants received FiO2 1.0, Supplemental 
Figure 1A – 2B, Supplemental Table) and PaCO2 values were lower in the <7 days group 
(Supplemental Figure 1C, Supplemental Table). There was no difference between the 
groups for haemoglobin levels and haematocrit, both decreased after cannulation and 
remained unchanged until discharge (Supplemental Table). Serum lactate concentration 
was higher (not significantly) in the 7+ days group prior to cannulation. The difference was 
not sustained during ECMO and the concentrations gradually dropped during the course of 
ECMO (pTime < 0.001). The 7+ days group experienced a greater number of adverse events 
(Table 3); median 4 (IQR 3-5) versus median 2 (IQR 0-2), p=0.001, received a larger volume 
of allogenic red cells, and clotting of the ECMO circuit (6 (60%) versus 6 (25%), p=0.002, 
Table 3). Patients in both groups had their PaO2/FiO2 ratio improved post weaning to 208 
(SD 86) for 7+ days group and 212 (SD 69) for <7 days group and the difference between 
the two groups was not statistically significant (p=0.944; Supplemental Table). 
Inflammation 
Haemoglobin metabolism There was a significant interaction between group and time for 
PFH concentrations (pgroup*time=0.02). Neonates requiring >7 days ECMO had higher levels at 
12 hours post cannulation (p12hr=0.05) but not thereafter (Supplemental Figure 1D, 
Supplemental Table). The >7 day group also had higher levels of serum bilirubin at 48 
hours (p48hr=0.03, Supplemental Figure 1E, Supplemental Table). There was no 
significant difference between groups with respect to plasma haptoglobin (Supplemental 








































































increased during the ECMO course (pTime<0.001). There was no difference between the 
groups for catalytic iron, ferritin, transferrin and total iron concentrations (Supplemental 
Table).  
Platelet, leucocyte and endothelial activation. Participants in the 7+ days group showed 
higher levels of platelet-granulocyte and platelet-monocyte aggregates (CD16/CD41 and 
CD14/CD41, respectively; pgroup=0.001, Supplemental Figure 1G – H, Supplemental 
Table), peaking at 24 hr post cannulation in the 7+ days group (p<0.001) but not thereafter. 
For levels of platelet-monocyte aggregates there was also a significant interaction between 
group and time (pgroup*time=0.028, Supplemental Table). Monocyte activation was also higher 
in the +7 days group (pgroup=0.018), with the greatest difference at 48 hours (p48hr = 0.02; 
Supplemental Figure 1I, Supplemental Table). There were no differences between groups 
for platelets activation measured with P-selectin/CD62P antibodies, CD11b (total leukocyte 
activation) and ICAM-1 (canonical endothelial cell activation, Supplemental Table). 
Inflammation biomarkers. There was a significant interaction between groups and time for 
the pro-inflammatory cytokines IL-8 (pgroup*time=0.003, Figure 2A, Supplemental Table) and 
MCP-1 (pgroup*time=0.013, Figure 2B, Supplemental Table) as well as the acute phase 
response biomarkers CRP (pgroup*time<0.001, Figure 2C and Supplemental Table) and IL-1b 
(pgroup*time<0.001, Figure 2D, Supplemental Table). For all these markers, participants in the 
<7 days group had significantly higher plasma concentrations of systemic inflammatory 
response and acute phase response biomarkers during the first 12 to 48 hours post 
cannulation versus those in the 7+ days group. TNFα and IL-1 levels were higher in the <7 
days (pgroup=0.018 and 0.013, respectively) with the test for interaction between group and 
time insignificant for TNF (Figure 2E, Supplemental Table). There was no difference 











































































In this single centre observational feasibility study we observed that neonates with PPHN 
who required prolonged ECMO support or who died (7+ days group) were more likely to 
have: 1. Presentation with congenital diaphragmatic hernia. 2. To be sicker at baseline with 
more severe hypoxia and hypercapnoea during ECMO. 3. A higher number of adverse 
events. 4. Higher PFH concentrations at 12 hours post cannulation but not thereafter and 
higher bilirubin concentrations at 48 hours without group differences in other markers of 
haemoglobin and iron metabolism. 5. Increased platelet (platelet-leukocyte aggregates24) 
and monocyte activation but no differences in canonical endothelial activation. 6. In an 
apparent paradox, lower plasma concentrations of biomarkers of the systemic inflammatory 
response (IL-8, MCP-1) and acute phase response (CRP, TNFα, IL-1) within 48 hours of 
cannulation. These findings did not support our primary hypothesis that the release of PFH 
by the ECMO circuit drives inflammatory responses that can prolong ECMO support. 
The study has several strengths. It is the first study to our knowledge that has systematically 
phenotyped cellular and platelet activation, cytokine responses, and haemoglobin 
metabolism in a cohort of neonates with PPHN requiring ECMO. The study results are 
counter to our initial hypotheses but these are supported by the rigorousness of our 
analytical methods, the high level of completeness of data, and the consistency of our 
results. A limitation of the study is that we were not able to measure our biomarkers prior to 
ECMO cannulation. This is because many neonates are placed on ECMO at their referring 
centre by a retrieval team and prior to assent or consent by legal guardians for sample 
collection. Stored samples collected at the time of cannulation were not suitable for the 
inflammation assays used in the study and a window of 12 hours post cannulation was 
therefore selected for the collection of baseline bloods for these assays. It is possible that 
the changes measured at this time will have altered dramatically from the pre-cannulation 
values, although this potential source of bias will have been present in both patient groups. 








































































relationship between the processes that we have measured and clinical outcomes. The 
small sample size is also a limitation. We cannot conclude that these findings would be 
replicated in a larger cohort. Nonetheless, our findings were remarkably consistent and 
highly statistically significant across measures of linked processes, indicating adequate 
power to detect differences in markers of inflammation even in this limited sample.  
The results have clinical application. First, outcomes in participants of the Mi-ECMO study 
were significantly associated with patient status before cannulation. Earlier use of ECMO 
support may be indicated in patients with congenital diaphragmatic hernia who were sicker 
at presentation relative to other groups. Second, patients with higher levels of systemic 
inflammation and acute phase inflammation where associated with shorter duration of 
ECMO support. This contrasts findings in adults requiring ECMO support25,26 where 
increased levels of pro-inflammatory cytokines27 are predictive of mortality, but is in 
agreement with the p-MIVAKI study where very different inflammatory responses were 
observed in neonates versus older children undergoing cardiac surgery with CPB.28 This 
may reflect different pathologies at baseline; MAS is primarily an inflammatory condition, 
whereas CDH is associated with lung hypoplasia and impaired chest wall dynamics, rather 
than a pathological response to ECMO.7 Alternatively, the results may represent the failure 
of the sicker patients in the 7+ days group to generate an inflammatory response. Third, the 
cytokine levels observed in the <7 days group were relatively low and were not associated 
with significant differences in downstream effectors of tissue inflammation IL-6 and IL-18, or 
measures of myocardial or renal injury between groups. These changes may reflect an 
inflammatory response that promotes repair rather than a dysregulated response that results 
in organ injury.29 Finally, the lower levels of inflammatory biomarkers are apparently 
contradictory to the higher PFH measured in the 7+ days group with levels comparable to 
those (0.3 mg mL-1) associated with organ injury in other paediatric ECMO cohorts.30 In 
mitigation, the difference between the groups was transient. In addition, the levels of 








































































sepsis or other inflammatory insults.31 Neonates exposed to inflammatory stress undergo a 
‘haptoglobin switch’ characterised by significant increases (20-30 fold) in protein expression 
as part of the acute phase response.32 These changes may precondition neonates against 
plasma free haem mediated tissue damage. A greater transfusion volume was observed in 
the 7+ day group. The importance of this finding is unclear; the absolute difference in the 
volume of red cells transfused was low and this may simply represent the effects of a 
prolonged stay in a critical care environment on circulating red cell mass in the 7+ day 
group. There was also no detectable difference in markers of haemolysis after 48 hours 
suggestive of consumption by the circuit. A final observation is the increased circulating 
levels of platelet-leukocyte aggregates, a sensitive measure of platelet activation 24 observed 
in the 7+ days group. PFH is known to activate platelets leading to adverse clinical 
outcomes,10,33,34 however whether these processes are linked in the current study is 
unproven.  
The study design dichotomising the analysis into two groups may have reduced the number 
of significantly associating biomarkers. That provides scope for future post hoc analyses. 
Also, in a larger study, it would be interesting to analyse the outcomes of patients with CDH 
and those with adverse events during ECMO. 
Conclusions Neonates requiring ECMO support for PPHN attributable to congenital 
diaphragmatic hernia, with higher levels of acidosis, PFH, platelet and leucocyte 
aggregation, and lower levels of systemic and acute phase inflammation are likely to require 
prolonged ECMO support. These findings highlight a knowledge gap with respect to the 
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Table and Figure legends  
Table 1. Demographics and diagnosis. Data is expressed as n (%) for binary variables, 
and mean(SD) or median (Q1-Q3) where appropriate for continuous variables. # n=1 from 7+ 
days group missing; ECMO: Extra-Corporeal Membrane Oxygenation; PPHN: Persistent 
Pulmonary Hypertension of the Newborn; RV – right ventricular; LV – left ventricular; SIMV – 
synchronised intermitent mechanical ventilation; PSV - Pressure support ventilation; HFOV - 
High frequency oscillatory ventilation 
Table 2. Baseline clinical characteristics. Data expressed as n(%) for binary variables, and 
mean(SD) or median (Q1-Q3) where appropriate for continuous variables. PIM2: Paediatric 
Index of Mortality v2; PMODS: Paediatric Multiple Organ Dysfunction Score (range from 0 to 
20); FiO2 - Fraction of inspired oxygen; PiO2 – partial pressure of oxygen; pCO2 (partial 
pressure of carbon dioxide); SaO2 – oxygen saturation; MAP - mean arterial pressure; ACT - 
activated clotting time. 
Table 3. Clinical outcomes. Data is expressed as n(%) for binary outcomes, and mean(SD) 
or median (Q1-Q3) where appropriate for continuous outcomes. RBC – red blood cells; FFP 
– fresh frozen plasma; SVT/AF - Supraventricular tachycardia/Atrial fibrillation. 
Figure 1. CONSORT Diagram showing patient flow through the study. 
Figure 2. Inflammation markers Geometric mean and data points for A – IL-8, B – MCP-1, 
C – CRP, D – IL-1, E – TNF) over time in patients who died or required prolonged stay 
(7+ days) vs those requiring less than 7 days (<7 days). pgroup refers to the p-value for the 
effect of group (7+ vs <7 days). pgroup*time refers to the p-value for the interaction between 
group and time. 
 
Supplemental Table: The table shows the mean (arithmetic or geometric for variables not 
requiring or requiring log transformation, respectively) and standard deviation (SD) for 








































































column shows the p-values from the linear mixed models with effects of group, and time and 
interaction of group*time adjusted for baseline. For variables in plasma free haemoglobin, 
cellular activation and Inflammation biomarkers, p-value shows the p-values from the 
linear mixed models with effects of group, and time and interaction group*time; and 
P_timept shows the p-value for the effect of groups at each measured time point. FValue – 
F-statistics with corresponding degrees of freedom (NumDF and DenDF). 
Supplemental Figure 1. Oxygenation, iron metabolism and cellular activation 
Estimated mean and data points for A – SaO2, B – PO2, C – pCO2, geometric mean and 
data points for D – Plasma Free Haemoglobin, E – Bilirubin, F – Haptoglobin, platelet (A – 
platelet-granulocyte aggregates CD16/CD41, B – platelet-monocyte aggregates) and 
monocyte activation biomarkers (C – CD14/CD41) over time in arterial blood of patients who 
died or required prolonged stay (7+ days) vs those requiring less than 7 days (<7 days). All 
participants received 100% FiO2. pgroup refers to the p-value for the effect of group (7+ vs <7 
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Figure 2 Click here to access/download;Figure;fig3.tif
Table 1. Demographics and diagnosis. Data is expressed as n (%) for binary variables, 
and mean(SD) or median (Q1-Q3) where appropriate for continuous variables. # n=1 from 7+ 
days group missing; ECMO: Extra-Corporeal Membrane Oxygenation; PPHN: Persistent 
Pulmonary Hypertension of the Newborn; RV – right ventricular; LV – left ventricular; SIMV – 
synchronised intermitent mechanical ventilation; PSV - Pressure support ventilation; HFOV - 
High frequency oscillatory ventilation 
 Parameter overall  
(n = 24) 
ECMO 7+ days           
(n = 10) 
ECMO 
<7days            
(n = 14) 
p-
value 
Age (day) on ECMO 2 (2 - 4) 2 (2 - 3) 2 (2 - 4) 0.890 
Gestational age (week) 40.6 (2.6) 40.2 (3.3) 40.9 (2.1) 0.508 
Sex - male 13 (54.2%) 5 (50.0%) 8 (57.1%) 0.999 
Ethnicity - White British 24 (100%) 10 (100%) 14 (100%) -- 
Weight at birth (kg) 3.2 (2.9 - 3.5) 3.1 (2.8 - 3.3) 3.2 (3.1 - 4.1) 0.102 
Diagnosis     
  Idiopathic PPHN 1 (4.2%) 0 (0.0%) 1 (7.1%) 0.999 
  Meconium Aspiration Syndrome 12 (50.0%) 0 (0.0%) 12 (85.7%) <0.001 
  Congenital Diaphragmatic Hernia 9 (37.5%) 8 (80.0%) 1 (7.1%) 0.001 
  Pneumonia/  Respiratory Distress Syndrome 4 (16.7%) 1 (10.0%) 3 (21.4%) 0.615 
  other diagnosis 4 (16.7%) 1 (10.0%) 3 (21.4%) 0.615 
Cardiac function     
  LV - moderate/severe impairment 2 (8.3%) 1 (10.0%) 1 (7.1%) 0.999 
  RV - moderate/severe impairment 3 (12.5%) 1 (10.0%) 2 (14.3%) 0.999 
Shunt#     
Left to right 8 (34.8%) 2 (22.2%) 6 (42.9%) 0.333 
Right to left 6 (26.1%) 3 (33.3%) 3 (21.4%)  
Bidirectional 5 (21.7%) 1 (11.1%) 4 (28.6%)  
None 4 (17.4%) 3 (33.3%) 1 (7.1%)  
Mechanical ventilation 24 (100.0%) 10 (100.0%) 14 (100.0%) -- 
Modality     
   SIMV 7 (29.2%) 0 (0.0%) 7 (50.0%) 0.006 
   PSV 1 (4.2%) 0 (0.0%) 1 (7.1%)  
   HFOV 16 (66.7%) 10 (100.0%) 6 (42.9%)  
Cannulation data     
Site – VV 3 (12.5%) 1 (10.0%) 2 (14.3%) 0.999 
   Blood priming 2 (8.3%) 2 (20.0%) 0 (0.0%) 0.163 




Table 2. Baseline clinical characteristics. Data expressed as n(%) for binary variables, and 
mean(SD) or median (Q1-Q3) where appropriate for continuous variables. PIM2: Paediatric 
Index of Mortality v2; PMODS: Paediatric Multiple Organ Dysfunction Score (range from 0 to 
20); FiO2 - Fraction of inspired oxygen; PiO2 – partial pressure of oxygen; pCO2 (partial 
pressure of carbon dioxide); SaO2 – oxygen saturation; MAP - mean arterial pressure; ACT - 
activated clotting time. 
Parameter n Overall  
(n=24) 
ECMO 7+ days           
(n = 10) 
ECMO <7days            
(n = 14) 
p-
value 
ICU admission      
PIM2 risk 24 0.39 (0.21 - 0.55) 0.37 (0.24 - 0.43) 0.43 (0.20 - 0.56) 0.623 
Haemodynamic instability prior to 
ECMO 
 12 (50.0%) 7 (70.0%) 5 (35.7%) 0.214 
PMODS PICU admission 23 8 (7 - 9) 9 (7 - 11) 7 (6 - 9) 0.122 
Lactates (mmol L-1) 24 4.0 (3.4) 5.3 (4.6) 3.1 (2.0) 0.191 
PaO2/FiO2 ratio 24 49.8 (25.4) 46.6 (27.7) 52.1 (24.5) 0.618 
Total bilirubin (umol L-1) 24 51 (29 - 70) 51 (34 - 59) 51 (17 - 70) 0.526 
Fibrinogen (g L-1) 23 1.8 (1.4 - 2.9) 1.5 (1.1 - 2.0) 2.5 (1.7 - 2.9) 0.085 
Urea (mmol L-1) 24 4.8 (1.6) 5.3 (1.4) 4.5 (1.6) 0.197 
Start of ECMO parameters      
MAP(mmHg) 23 48 (44 - 61) 59 (40 - 75) 46 (45 - 50) 0.289 
FiO2 on ECMO (%) 23 100 (100 - 100) 100 (100 - 100) 100 (100 - 100)  
ACT (sec) 17 304.3 (62.9) 320.3 (36.4) 293.1 (76.2) 0.398 
Pump flow (ml min-1) 22 362.3 (83.5) 358.0 (59.6) 365.8 (101.9) 0.833 
Sweep gas (ml min-1) 22 300 (200 - 300) 250 (200 - 300) 300 (225 - 310) 0.244 
RMP (revolutions min-1) 22 2,786 (361) 2,840 (423) 2,742 (312) 0.537 
Start of ECMO - arterial blood gas      
pH 24 7.3 (0.12) 7.2 (0.14) 7.3 (0.08) 0.018 
PiO2 (kPa) 24 6.1 (1.2) 6.0 (1.3) 6.2 (1.2) 0.710 
pCO2 (kPa) 24 6.4 (1.7) 7.2 (2.1) 5.8 (0.9) 0.078 
SaO2 (%) 23 84.3 (7.4) 80.9 (5.1) 86.9 (8.0) 0.050 
Glu (mmol L-1) 24 7.9 (3.2) 8.0 (2.8) 7.9 (3.5) 0.925 
HCO3 (mmol L-1) 24 20.8 (3.8) 21.1 (4.4) 20.5 (3.4) 0.700 
Biochemistry      
C-reactive protein (mg L-1) 24 16 (5 - 47) 6 (5 - 15) 39 (11 - 48) 0.019 
Platelet count (x109 L-1) 24 152.6 (83.1) 139.9 (99.1) 161.6 (72.1) 0.539 
Creatinine (umol L-1) 24 63 (44 - 71) 53 (43 - 66) 66 (51 - 73) 0.358 
Adjusted Calcium (mmol L-1) 23 2.24 (0.17) 2.19 (0.16) 2.27 (0.19) 0.326 
Alkaline Phosphatase (iu L-1) 23 131 (75 - 207) 107 (66 - 131) 198 (113 - 613) 0.030 
Haemoglobin (g L-1) 24 148.0 (37.5) 151.5 (33.0) 145.4 (41.5) 0.705 
Haematocrit (L L-1) 21 0.44 (0.12) 0.45 (0.11) 0.43 (0.14) 0.725 
International Normalised Ratio 23 1.8 (0.5) 1.7 (0.4) 1.8 (0.6) 0.661 
Activated partial thromboplastin time 22 1.9 (1.2 - 6) 1.8 (1.5 - 6) 1.9 (1.2 - 5.6) 0.357 
Table 2
 
Table 3. Clinical outcomes. Data is expressed as n(%) for binary outcomes, and mean(SD) 
or median (Q1-Q3) where appropriate for continuous outcomes. RBC – red blood cells; FFP 
– fresh frozen plasma; SVT/AF - Supraventricular tachycardia/Atrial fibrillation. 
Clinical outcomes 
overall  
(n = 24) 
ECMO  
7+ days           
 (n = 10) 
ECMO 
<7days            
(n = 14) 
p-
value 
Transfusion     
RBC transfusion 24 (100.0%) 10 (100.0%) 14 (100.0%) -- 
RBC transfusion volume 289.6 (241.0) 479.2 (268.2) 154.1 (74.6) 0.004 
any non-RBC transfusion 20 (83.3%) 10 (100.0%) 10 (71.4%) 0.114 
FFP transfusion 16 (66.7%) 7 (70.0%) 9 (64.3%) 0.999 
Platelet transfusion 19 (79.2%) 10 (100.0%) 9 (64.3%) 0.053 
Cryoprecipitate transfusion 13 (54.2%) 8 (80.0%) 5 (35.7%) 0.047 
Complications     
SVT/AF requiring treatment 1 (4.2%) 1 (10.0%) 0 (0.0%) 0.417 
ECMO circuit clotting 6 (25.0%) 6 (60.0%) 0 (0.0%) 0.002 
Inotrope 20 (83.3%) 10 (100.0%) 10 (71.4%) 0.114 
Vasopressor 17 (70.8%) 9 (90.0%) 8 (57.1%) 0.172 
Tracheostomy 1 (4.2%) 1 (10.0%) 0 (0%) 0.417 
Pneumothorax or effusion requiring drainage 5 (20.8%) 5 (50.0%) 0 (0%) 0.006 
Acute kidney injury 3 (12.5%) 3 (30.0%) 0 (0%) 0.059 
Peptic Ulcer / GI Bleed / Perforation 2 (8.3%) 2 (20.0%) 0 (0%) 0.163 
Transient ischaemic attack 1 (4.2%) 1 (10.0%) 0 (0%) 0.417 
Excess bleeding (400ml hr-1 for 1 hour or 
200ml hr-1 for 4 hours)) 
1 (4.2%) 1 (10.0%) 0 (0%) 0.417 
Wound requiring treatment 1 (4.2%) 1 (10.0%) 0 (0%) 0.417 
Residual anatomical abnormalities requiring 
surgery 
1 (4.2%) 1 (10.0%) 0 (0%) 0.417 
Catheter related bloods stream infection 1 (4.2%) 1 (10.0%) 0 (0%) 0.417 
Any complications 20 (83.3%) 10 (100.0%) 10 (71.4%) 0.114 
Number of complications 2 (1.5 - 4) 4 (3 - 5) 2 (0 - 2) 0.001 
Outcome     
Chest open 1 (4.2%) 1 (10.0%) 0 (0.0%) 0.417 
Survival to discharge 21 (87.5%) 7 (70.0%) 14 (100.0%) 0.059 
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